NasdaqGS:ZYMEBiotechs
Is New ZW191 and Pan-RAS ADC Data Acceptance Shifting The Investment Case For Zymeworks (ZYME)?
In March 2026, Zymeworks Inc. reported that an oral presentation of new Phase 1 clinical data for its folate receptor alpha-targeting antibody-drug conjugate ZW191, along with six additional abstracts from its wholly owned oncology R&D portfolio, had been accepted for the American Association for Cancer Research Annual Meeting in San Diego.
The breadth of clinical and preclinical data, spanning ZW191 and multiple pan-RAS inhibitor antibody-drug conjugate candidates across RAS-mutated and...